CRVO CervoMed Inc.
Price Chart
Executive Summary
CervoMed Inc. (CRVO) entered into a securities purchase agreement to sell $10.55 million in units at $3.14/unit, comprising common stock (or pre-funded warrants), Series B warrants (exercise price $3.32), and Series C warrants (exercise price $3.14). The company with a $27M market cap is raising nearly 40% of its market value, which is highly dilutive. Proceeds fund R&D of its clinical-stage candidate neflamapimod, working capital, and general corporate purposes.
Key Financial Metrics
Actionable Insight
Massive dilutive financing for a micro-cap biotech signals severe cash burn and limited financing alternatives. The 5-year warrants (Series B at $3.32, Series C at $3.14) create significant overhang. Watch for potential reverse split risk if the stock trades below $1.00 for 30 consecutive days, and monitor whether the company is able to progress neflamapimod through clinical milestones to justify the massive equity raise.
Key Facts
- Raised $10.55M via sale of 3,360,377 units at $3.14/unit
- Units include 1,767,514 common shares + 1,592,863 pre-funded warrants + 3,360,377 Series B warrants ($3.32 strike) + 3,360,377 Series C warrants ($3.14 strike)
- Series B warrants expire June 11, 2031 (5-year term); Series C warrants also expire June 11, 2031
- Issuance represents ~190%+ dilution to current shares outstanding if all warrants exercised
- Use of proceeds: fund R&D of neflamapimod, working capital, general corporate purposes
- Directors and officers subject to lock-up agreements
- Company filed an 8-K on Item 1.01, 3.02, 7.01, 8.01, 9.01
Financial Impact
$10.55M gross proceeds; market cap ~$27M; fully diluted share count more than doubles, creating massive dilution
Risk Factors
- Immediate dilution of ~190%+ from current shares if all warrants exercised
- Potential for further dilution as the company may need additional capital
- Warrant overhang (6.72M additional shares exercisable at $3.14–$3.32) caps upside
- Clinical-stage biotech with no approved products; neflamapimod may fail in trials
- Nasdaq minimum bid price compliance risk with ~$3 stock and $27M market cap
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-020080 |
| Exhibit: ex_974986.htm | 0001437749-26-020080 |
| Exhibit: ex_974987.htm | 0001437749-26-020080 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 18, 2026
2d ago
|
Press Release
| $7.44 awaiting T+1 | awaiting T+1 | — | $4.24 (+43.01%) |
|
Jun 18, 2026
2d ago
|
8-K
| $4.03 awaiting T+1 | awaiting T+1 | — | $4.24 (+5.21%) |
|
Jun 15, 2026
5d ago
|
8-K
| $4.52 $3.81 | ▼ −15.71% | ▼ −14.46% | $4.24 (−6.19%) |
|
Jun 10, 2026
10d ago
|
8-K
| $2.25 $2.44 | ▼ −8.44% | ▼ −6.74% | $4.24 (−88.44%) |
|
May 18, 2026
4w ago
|
8-K
| $2.89 $3.24 | ▼ −12.11% | ▼ −11.07% | $4.24 (−46.71%) |
|
May 18, 2026
4w ago
|
Press Release
| $3.04 $2.89 | ▼ −4.93% | ▼ −4.28% | $4.24 (+39.47%) |
|
Apr 22, 2026
8w ago
|
8-K
| $3.85 $3.88 | ▲ +0.78% | ▼ −0.01% | $4.24 (+10.13%) |
|
Apr 22, 2026
8w ago
|
Press Release
| $3.94 $3.85 | ▼ −2.28% | ▼ −1.89% | $4.24 (+7.61%) |
|
Apr 7, 2026
10w ago
|
8-K
| $4.04 $4.03 | ▼ −0.25% | ▼ −0.82% | $4.24 (+4.95%) |
|
Mar 17, 2026
13w ago
|
Press Release
| $4.53 $4.24 | ▼ −6.40% | ▼ −5.00% | $4.24 (−6.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access